Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
ONCY Stock Chart & Stats
$0.99
-$0.03(-3.70%)
At close: 4:00 PM EST
$0.99
-$0.03(-3.70%)
Day’s Range― - ―
52-Week Range$0.33 - $1.51
Previous CloseN/A
Volume216.96K
Average Volume (3M)861.50K
Market Cap
$106.70M
Enterprise Value$133.56M
Total Cash (Recent Filing)$12.35M
Total Debt (Recent Filing)$835.00K
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Mar 05, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding107,606,380
10 Day Avg. Volume655,854
30 Day Avg. Volume861,499
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)16.80
Price to Sales (P/S)0.00
P/FCF Ratio-3.69
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.77
Forecast
1Y Price Target
$5.50Price Target Upside455.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsUpdated trial data showing notably higher objective response rates and durable complete remissions in heavily pretreated anal and colorectal cancer patients suggest potential to support an accelerated approval pathway if reproduced in registrational studies.
Mechanism And Delivery AdvantagesIntravenous delivery combined with evidence of viral replication and immune activation indicates pelareorep can reach metastatic tumors and enhance response to checkpoint inhibitors, supporting its role as a backbone immunotherapy.
Regulatory PathwayClear FDA alignment on the pivotal trial design for first-line metastatic pancreatic cancer reduces regulatory uncertainty and provides a defined path toward potential approval.
Bears Say
Capital And Dilution RiskEstimated cash burn of about $33 million versus roughly C$12 million in cash suggests a tight cash runway and raises the likelihood of near-term financing and shareholder dilution.
Commercialization And Reimbursement RiskClinical development risk, competitor advances, reimbursement and pricing uncertainty, and potential trial disruptions could materially limit commercial prospects even if clinical efficacy is established.
Data RobustnessEfficacy signals derive from small patient cohorts, creating substantial uncertainty until larger, randomized registration trials confirm benefit.
Oncolytics Biotech News
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.33 and its highest was $1.51 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $106.70M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Mar 05, 2026 which is in 50 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Nov 12, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.062 by -$0.038.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -0.06.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 107,606,380 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.062. Following the earnings report the stock price went down -4.846%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oncolytics Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (455.56% Upside)
$5.50 (455.56% Upside)
Blogger Sentiment
Bullish
ONCY Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 12.4%
Last 30 Days ▲ 12.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.96%
12-Months-Change
Fundamentals
Return on Equity
-745.66%
Trailing 12-Months
Asset Growth
-39.74%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
ONCY Stock 12 Month Forecast
Average Price Target
$5.50
▲(455.56% Upside)
Technical Analysis
Atossa Therapeutics
―
Oramed Pharm
―
Atara Biotherapeutics
―
Zentalis Pharmaceuticals
―
Prelude Therapeutics
―
Ownership Overview
1.62% Insiders
0.06% Mutual Funds
0.89% Other Institutional Investors
97.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---